

Datasheet for 609-1302**Human IgG (H&L) Antibody Peroxidase Conjugated****Overview**

Description:	Goat Anti-Human IgG (H&L) Antibody Peroxidase Conjugated - 609-1302
Item No.:	609-1302
Size:	2.0 mg
Applications:	Dot Blot, ELISA
Reactivity:	Human
Host Species:	Goat

Product Details**Background:**

Anti-Human IgG (H&L) peroxidase conjugated antibody generated in goat detects specifically human IgG. Secreted as part of the adaptive immune response by plasma B cells, immunoglobulin G constitutes 75% of serum immunoglobulins. Immunoglobulin G binds to viruses, bacteria, as well as fungi and facilitates their destruction or neutralization via agglutination (and thereby immobilizing them), activation of the complement cascade, and opsonization for phagocytosis. The whole IgG molecule possesses both the F(c) region, recognized by high-affinity Fc receptor proteins, as well as the F(ab) region possessing the epitope-recognition site. Both the Heavy and Light chains of the antibody molecule are present. Secondary Antibodies are available in a variety of formats and conjugate types. When choosing a secondary antibody product, consideration must be given to species and immunoglobulin specificity, conjugate type, fragment and chain specificity, level of cross-reactivity, and host-species source and fragment composition. This anti-Human peroxidase conjugated secondary antibody is ideal for investigators who routinely perform titration assays, western-blot, immunoprecipitation and more generally immunoassays.

Synonyms:	goat anti-Human IgG peroxidase conjugated Antibody, goat anti-Human IgG Antibody HRP conjugation
Host Species:	Goat
Specificity:	IgG (H&L)
Conjugate:	Peroxidase (HRP)
Clonality:	Polyclonal
Format:	IgG

Target Details

Reactivity:	Human
Immunogen Type:	Native Protein
Immunogen:	Anti-Human IgG (H&L) was produced by repeated immunization with human IgG whole molecule in goat.
Purity/Specificity:	This product was prepared from monospecific antiserum by immunoaffinity chromatography using Human IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Peroxidase, anti-Goat Serum, Human IgG and Human Serum.

Application Details

Tested Applications:	Dot Blot, ELISA
Application Note:	Anti-Human IgG (H&L) peroxidase conjugated antibody has been tested by dot blot and ELISA and is suitable for immunoblotting (western or dot blot), ELISA, immunoperoxidase electron microscopy and immunohistochemistry as well as other peroxidase-antibody based enzymatic assays requiring lot-to-lot consistency.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	1:20,000 - 1:80,000
IHC:	1:1,000 - 1:5,000
WB:	1:5,000 - 1:25,000

Formulation

Physical State:	Lyophilized
Concentration:	2.0 mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Gentamicin Sulfate. Do NOT add Sodium Azide!
Stabilizer:	10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free
Reconstitution Volume:	1.0 mL
Reconstitution Buffer:	Restore with deionized water (or equivalent)


Shipping & Handling

Shipping Condition: Ambient

Storage Condition: Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

Expiration: Expiration date is one (1) year from date of receipt.

Images



ELISA

ELISA results of purified Goat anti-Human IgG Antibody Peroxidase conjugated tested against BSA-conjugated peptide of immunizing peptide. Each well was coated in duplicate with 1.0 µg of Human IgG (p/n 009-0102). The starting dilution of antibody was 5µg/ml and the X-axis represents the Log10 of a 3-fold dilution. This titration is a 4-parameter curve fit where the IC50 is defined as the titer of the antibody. Assay performed using 3% fish gelatin as blocking buffer and TMB substrate p/n TMBE-1000.

Dot Blot

Dot Blot of Human IgG. Lane 1: 100ng. Lane 2: 33.3ng. Lane 3: 11.1ng. Lane 4: 3.7ng. Lane 5: 1.23ng. Secondary Antibody: 609-1302 HRP Gt-a-Hu IgG 1:1,000. Blocking Buffer: BlockOut MB-073 for 1 hour RT.

100 ng 33.3 ng 11.1 ng 3.70 ng 1.23 ng



References

- Tse AL et al. Powassan Virus Seroprevalence in a U.S. Servicemember Population at High Risk for Tick Exposure. *medRxiv [Preprint]*. (2026)
- Henning A et al. Human Fcγ-receptors selectively respond to C-reactive protein isoforms. *Front Immunol.* (2025)
- Phan IQ et al. In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19. *Sci Rep.* (2021)
- Fox A. et al. Evidence of a significant secretory-IgA-dominant SARS-CoV-2 immune response in human milk following recovery from COVID-19. *medRxiv* (2020)
- Jian L, Xiujuan S, Yuangang Y, et al. Evaluation of antibody detection against the NDO-BSA, LID-1 and NDO-LID antigens as confirmatory tests to support the diagnosis of leprosy in Yunnan province, southwest China. *Trans R Soc Trop Med Hyg.* (2020)
- Serrano-Coll H et al. Anti-natural octyl disaccharide-leprosy IDRI diagnostic (NDO-LID) antibodies as indicators of leprosy reactions and neuritis. *Trans R Soc Trop Med Hyg.* (2017)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.